This contract is conducting a Phase 2 clinical trial to compare the relative safety of high dose chemotherapy followed by autologous hematopoietic stem cell transplant to currently available immunosuppressive immunomodulatory therapies for the treatment of severe, treatment refractory, steroid dependent systemic lupus erythematosus. Secondary endpoints will evaluate trends of relative efficacy. Mechanistic studies are planned to evaluate both B and T cell reconstitution.
